{"product_id":"lucivora-vorasidenib","title":"LuciVora (Vorasidenib)","description":"\u003ch2\u003eAbout Vorasidenib\u003c\/h2\u003e\u003cp\u003eVorasidenib is an oral, brain-penetrant, dual inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) and 2 (IDH2) enzymes, approved for treating grade 2 IDH-mutant astrocytoma or oligodendroglioma in adults and children 12 years and older, following surgery. \u003c\/p\u003e\u003ch2\u003eAdult\u003c\/h2\u003e\u003ch3\u003eAstrocytoma or Oligodendroglioma\u003c\/h3\u003e\u003cp\u003eIndicated for Grade 2 astrocytoma or oligodendroglioma with susceptible isocitrate dehydrogenase (IDH)-1 or IDH-2 mutation following surgery including biopsy, sub-total resection, or gross total resection\u003c\/p\u003e\u003cp\u003e40 mg PO qDay until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eRecommended dosage reductions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst reduction: 20 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond reduction: 10 mg PO qDay\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue if second dosage reduction not tolerated\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatotoxicity\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eALT or AST \u0026gt;ULN to 3 x ULN without concurrent total bilirubin \u0026gt;2 x ULN\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eContinue current dose\u003c\/li\u003e\n\u003cli\u003eMonitor liver function tests (LFTs) weekly until recovery to\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eALT or AST \u0026gt;3-5 x ULN without concurrent total bilirubin \u0026gt;2 x ULN\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eHold until recovery to ≤Grade 1 or baseline\u003c\/li\u003e\n\u003cli\u003eResume at same dose for recovery ≤28 days or at reduced dose for recovery \u0026gt;28 days\u003c\/li\u003e\n\u003cli\u003eRecurrence: Hold therapy until recovery to ≤Grade 1 or baseline and resume at reduced dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eALT or AST \u0026gt;5-20 x ULN without concurrent total bilirubin \u0026gt;2 x ULN\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eHold therapy until recovery to ≤Grade 1 or baseline\u003c\/li\u003e\n\u003cli\u003eResume at reduced dose for recovery ≤28 days or permanently discontinue for recovery \u0026gt;28 days\u003c\/li\u003e\n\u003cli\u003eRecurrence: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eALT or AST \u0026gt;3-20 x ULN with concurrent total bilirubin \u0026gt;2 x ULN\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eHold therapy until recovery to ≤Grade 1 or baseline\u003c\/li\u003e\n\u003cli\u003eResume at reduced dose\u003c\/li\u003e\n\u003cli\u003eRecurrence: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eAny ALT or AST \u0026gt;20 x ULN\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eOther adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 3\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eHold therapy until recovery to ≤Grade 1 or baseline\u003c\/li\u003e\n\u003cli\u003eResume at reduced dose\u003c\/li\u003e\n\u003cli\u003eRecurrence: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 4\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eCrCl \u0026gt;40 mL\/min: No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eCrCl ≤40 mL\/min or on dialysis: Not studied; monitor for adverse reactions and adjust dose as recommended\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild or moderate (Child-Pugh class A or B): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (Child-Pugh class C): Not studied; monitor for adverse reactions and adjust dose as recommended\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003cp\u003eEvaluate blood chemistry and LFTs before initiating\u003c\/p\u003e\u003ch4\u003ePatient selection\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eTest for presence of IDH1 or IDH2 mutations in tumor specimens\u003c\/li\u003e\u003c\/ul\u003e\u003ch2\u003ePediatric\u003c\/h2\u003e\u003ch3\u003eAstrocytoma or Oligodendroglioma\u003c\/h3\u003e\u003cp\u003eIndicated for Grade 2 astrocytoma or oligodendroglioma with susceptible isocitrate dehydrogenase (IDH)-1 or IDH-2 mutation following surgery including biopsy, sub-total resection, or gross total resection in patients ≥12 years\u003c\/p\u003e\u003cp\u003e≥40 kg: 40 mg PO qDay\u003c\/p\u003e\u003cp\u003e\u0026lt;40 kg: 20 mg PO qDay\u003c\/p\u003e\u003cp\u003eContinue until disease progression or unacceptable toxicity\u003c\/p\u003e\u003cp\u003eSafety and efficacy not established in patients \u0026lt;12 years\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003ch4\u003eRecommended dosage adjustments\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003e≥40 kg\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst reduction: 20 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond reduction: 10 mg PO qDay\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003e\u0026lt;40 kg\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eFirst reduction: 10 mg PO qDay\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue if reduced dose not tolerated\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatotoxicity\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eALT or AST \u0026gt;ULN to 3 x ULN without concurrent total bilirubin \u0026gt;2 x ULN\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eContinue current dose\u003c\/li\u003e\n\u003cli\u003eMonitor liver function tests (LFTs) weekly until recovery to\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eALT or AST \u0026gt;3-5 x ULN without concurrent total bilirubin \u0026gt;2 x ULN\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eHold until recovery to ≤Grade 1 or baseline\u003c\/li\u003e\n\u003cli\u003eResume at same dose for recovery ≤28 days or at reduced dose for recovery \u0026gt;28 days\u003c\/li\u003e\n\u003cli\u003eRecurrence: Hold therapy until recovery to ≤Grade 1 or baseline and resume at reduced dose\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eALT or AST \u0026gt;5-20 x ULN without concurrent total bilirubin \u0026gt;2 x ULN\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eHold therapy until recovery to ≤Grade 1 or baseline\u003c\/li\u003e\n\u003cli\u003eResume at reduced dose for recovery ≤28 days or permanently discontinue for recovery \u0026gt;28 days\u003c\/li\u003e\n\u003cli\u003eRecurrence: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eALT or AST \u0026gt;3-20 x ULN with concurrent total bilirubin \u0026gt;2 x ULN\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eHold therapy until recovery to ≤Grade 1 or baseline\u003c\/li\u003e\n\u003cli\u003eResume at reduced dose\u003c\/li\u003e\n\u003cli\u003eRecurrence: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eAny ALT or AST \u0026gt;20 x ULN\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eOther adverse reactions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 3\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eHold therapy until recovery to ≤Grade 1 or baseline\u003c\/li\u003e\n\u003cli\u003eResume at reduced dose\u003c\/li\u003e\n\u003cli\u003eRecurrence: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 4\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eCrCl \u0026gt;40 mL\/min: No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eCrCl ≤40 mL\/min or on dialysis: Not studied; monitor for adverse reactions and adjust dose as recommended\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild or moderate (Child-Pugh class A or B): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (Child-Pugh class C): Not studied; monitor for adverse reactions and adjust dose as recommended\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch3\u003eDosing Considerations\u003c\/h3\u003e\u003cp\u003eEvaluate blood chemistry and LFTs before initiating\u003c\/p\u003e\u003ch4\u003ePatient selection\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eTest for presence of IDH1 or IDH2 mutations in tumor specimens\u003c\/li\u003e\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797957603371,"sku":"RL3320250408","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-04-0564.jpg?v=1787022288","url":"https:\/\/xomeds.com\/products\/lucivora-vorasidenib","provider":"XOMEDS","version":"1.0","type":"link"}